2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.107 Jesse Sussell Abstract

PP01.107 Jesse Sussell Abstract

Pdf Summary

A retrospective analysis was conducted using data from the Flatiron Health-Foundation Medicine lung clinico-genomic database to examine the characteristics and treatment patterns of patients with early non-small cell lung cancer (eNSCLC) based on their biomarker status. The study included 1,916 patients diagnosed with stage I-IIIa NSCLC between 2011-2023.<br /><br />The results showed that the majority of patients were treated in the community setting (87%) and had commercial insurance (55%). Most patients were white (67%) and had a median follow-up of 29.6 months. The distribution of biomarker status among the patients was as follows: ALK - 2.2%, EGFR - 16.4%, KRAS - 23.8%, and wild-type (negative for the listed biomarkers) - 57.6%.<br /><br />Patients with ALK alterations were younger compared to other biomarker groups, with a median age of 61. Smoking history was more common in KRAS and wild-type patients, while it was less common in ALK and EGFR patients. KRAS G12C was the most common variant of KRAS mutations, and KRAS non-G12C was more common in stage I and III patients, while EGFR was more common in stage II patients.<br /><br />Mutations were more common in Asian patients, with 67% positive for any biomarker, compared to 40-42% for others. ALK and EGFR alterations were also more prevalent among Asian patients compared to non-Asian patients.<br /><br />Adjuvant treatment varied among patients, with half receiving no treatment and 38% receiving adjuvant chemotherapy. There were no apparent differences in treatment patterns based on biomarker status. The most common chemotherapy regimens used were cisplatin and pemetrexed, followed by carboplatin and pemetrexed.<br /><br />In conclusion, stratifying eNSCLC patients based on biomarker status revealed significant differences in demographic and clinical characteristics. Further research is needed to better understand the role of biomarkers in the pathology of eNSCLC and to optimize treatment strategies for these patients.

Keywords

retrospective analysis

lung cancer

biomarker status

treatment patterns

NSCLC

demographic characteristics

chemotherapy regimens

ALK alterations

EGFR alterations

KRAS alterations